

Gedeon Richter Plc. announces expansion plans for its biotechnology plant in Debrecen

Budapest, 10 March 2016 – Gedeon Richter Plc. intends to expand its capacities dedicated to biosimilar development and manufacturing in the town of Debrecen via a capital expenditure program worth HUF 15 billion. These facilities were initially inaugurated in 2012. The planned investment is expected to create 125 new jobs and involves a near doubling of the biotechnological manufacturing capacities while simultaneously establishing an analytical facility to evaluate the substances produced.

Mr Péter Szijjártó, Minister of Foreign Affairs and Trade and Mr Erik Bogesch, Managing Director of Gedeon Richter Plc. will sign a related agreement which provides for a state subsidy amounting to close to HUF 5 billion in accordance with EKD programme (investments supported by individual Government decisions).

About Richter

Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Having reached a market capitalisation of Euro 3.3 billion (US\$ 3.6 billion) by the end of 2015, Richter's consolidated sales were approximately Euro 3.3 billion (US\$ 3.6 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including gynaecology, central nervous system, and cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in biosimilar product development.

For more information:

Investors:

Katalin Ördög +36 1 431 5680